Estradiol/norethisterone transdermal - Johnson & Johnson

Drug Profile

Estradiol/norethisterone transdermal - Johnson & Johnson

Alternative Names: Evorel Conti; Systen Conti

Latest Information Update: 12 Nov 1998

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson
  • Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Norpregnenes; Oral contraceptives; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 12 Nov 1998 Launched for Postmenopausal osteoporosis in United Kingdom (Transdermal)
  • 16 Apr 1998 A clinical study has been added to the Women's Health pharmacodynamics section
  • 15 Apr 1998 A study has been added to the Women's Health therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top